Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
HMPL-523 inhibits SYK, resulting in decreased tumor cell proliferation and migration (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HMPL-523||SYK Inhibitor 14||HMPL-523 inhibits SYK, resulting in decreased tumor cell proliferation and migration (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||B-cell lymphoma||not applicable||HMPL-523||Preclinical - Cell line xenograft||Actionable||In a preclinical study, HMPL-523 decreased viability of SYK-dysregulated B-cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (Blood Dec 2016, 128 (22) 3970).||detail...|
|ETV6 - SYK||Advanced Solid Tumor||sensitive||HMPL-523||Preclinical - Cell culture||Actionable||In a preclinical study, HMPL-523 decreased viability of cells expressing ETV6-SYK in culture (Blood Dec 2016, 128 (22) 3970).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03779113||Phase Ib/II||HMPL-523||An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma||Recruiting|